DE69832796D1 - Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen - Google Patents

Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen

Info

Publication number
DE69832796D1
DE69832796D1 DE69832796T DE69832796T DE69832796D1 DE 69832796 D1 DE69832796 D1 DE 69832796D1 DE 69832796 T DE69832796 T DE 69832796T DE 69832796 T DE69832796 T DE 69832796T DE 69832796 D1 DE69832796 D1 DE 69832796D1
Authority
DE
Germany
Prior art keywords
pct
mizolastine
inflammation
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832796T
Other languages
English (en)
Other versions
DE69832796T2 (de
Inventor
Itzchak Angel
Sonia Arbilla
Luc Even
Jon Goldhill
Philippe Pichat
Nigel Roome
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of DE69832796D1 publication Critical patent/DE69832796D1/de
Application granted granted Critical
Publication of DE69832796T2 publication Critical patent/DE69832796T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69832796T 1997-04-17 1998-04-16 Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen Expired - Lifetime DE69832796T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9704801 1997-04-17
FR9704801A FR2762214B1 (fr) 1997-04-17 1997-04-17 Utilisation de la mizolastine pour la preparation d'un medicament destine au traitement de l'inflammation
PCT/FR1998/000765 WO1998047511A1 (fr) 1997-04-17 1998-04-16 Utilisation de la mizolastine pour la preparation d'un medicament destine au traitement de l'inflammation

Publications (2)

Publication Number Publication Date
DE69832796D1 true DE69832796D1 (de) 2006-01-19
DE69832796T2 DE69832796T2 (de) 2006-08-31

Family

ID=9506075

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69832796T Expired - Lifetime DE69832796T2 (de) 1997-04-17 1998-04-16 Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen

Country Status (11)

Country Link
US (1) US6140335A (de)
EP (1) EP1007047B1 (de)
JP (2) JP2001523242A (de)
AT (1) ATE312611T1 (de)
AU (1) AU7436098A (de)
DE (1) DE69832796T2 (de)
DK (1) DK1007047T3 (de)
ES (1) ES2253816T3 (de)
FR (1) FR2762214B1 (de)
WO (1) WO1998047511A1 (de)
ZA (1) ZA983211B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958820A1 (de) * 1998-05-19 1999-11-24 Sanofi-Synthelabo Verwendung von einem Imidazolderivat zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunerkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
JP2009292827A (ja) 2009-12-17
JP5271188B2 (ja) 2013-08-21
JP2001523242A (ja) 2001-11-20
US6140335A (en) 2000-10-31
AU7436098A (en) 1998-11-13
FR2762214B1 (fr) 2000-10-06
EP1007047A1 (de) 2000-06-14
FR2762214A1 (fr) 1998-10-23
ATE312611T1 (de) 2005-12-15
DK1007047T3 (da) 2006-05-08
EP1007047B1 (de) 2005-12-14
DE69832796T2 (de) 2006-08-31
WO1998047511A1 (fr) 1998-10-29
ES2253816T3 (es) 2006-06-01
ZA983211B (en) 1998-10-22

Similar Documents

Publication Publication Date Title
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE164067T1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69616376T2 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69100364D1 (de) Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE59508961D1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
TR200200278T2 (tr) Kalsilitik bileşimler
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
DE50103012D1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
NO990450L (no) Behandling av sinnslidelser
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE239458T1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen
DE69328205D1 (de) Rektale Flunisolid-Zubereitung zur Behandlung entzündlicher Darmerkrankungen
DE69620394D1 (de) Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

R082 Change of representative

Ref document number: 1007047

Country of ref document: EP

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, DE